|
Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s pharmaceutical products include chemically-synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor T-cell therapies. Co.'s primary product includes Eliquis® - Eliquis (apixaban), which is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.
Preferred: BMYMP
|
|
|
BMY Next Dividend Date » (Projection based upon history) BMY Dividend Growth Rate » Quotes delayed 20 minutes |
Hold (2.35 out of 4) 8th percentile
(ranked lower than approx. 92% of all stocks covered)
Analysts' Target Price: BMY Forecast Based on data provided by Zacks Investment Research via Quandl.com |
Projection:
BMY Next Dividend Date |